Neurology Medical News about Parkinsons disease;levodopa-treated patients;entacapone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: A long-term, retrospective analysis
European Journal of Neurology, 07/02/09

Nissinen H et al. – Data suggest that early vs delayed addition of entacapone to levodopa/ dopa-decarboxylase inhibitor (DDCI) in Parkinson's disease (PD) pts with wearing-off provides a modest clinical benefit over levodopa/DDCI that is maintained for up to 5 yrs.

Methods

Data analysis from 3 clinical trials in PD pts with wearing-off to determine whether early enhancement of levodopa therapy with entacapone can lead to better long-term outcomes than delayed entacapone treatment
Post-hoc analysis of pooled data from 3 randomized, double-blind, placebo-controlled studies and their long-term, open-label extension phases
In all 3 studies, DDCI pts first randomized to entacapone ('early-start' group) or placebo ('delayed-start' group) for initial 6-mo double-blind phase, then open-label levodopa/DDCI and entacapone treatment for up to 5 yrs for all pts

Results

Total of 488 PD pts with wearing-off analyzed
Statistically significant benefit of early initiation of levodopa/DDCI and entacapone
Improvement in Unified Parkinson's Disease Rating Scale Part III (motor) score of ?1.66 points vs delayed-start treatment group
Levodopa/DDCI and entacapone therapy well tolerated
No excess of dyskinesia in early-start group

Next >>
Relationship between ALS and the degree of cognitive impairment,...